Carvacho Ingrid, Piesche Matthias
Department of Biology and Chemistry Faculty of Basic Sciences Universidad Católica del Maule Talca Chile.
Biomedical Research Laboratories, Medicine Faculty Universidad Católica del Maule Talca Chile.
Clin Transl Immunology. 2021 Mar 18;10(3):e1240. doi: 10.1002/cti2.1240. eCollection 2021.
The new coronavirus SARS-CoV-2 is a global pandemic and a severe public health crisis. SARS-CoV-2 is highly contagious and shows high mortality rates, especially in elderly and patients with pre-existing medical conditions. At the current stage, no effective drugs are available to treat these patients. In this review, we analyse the rationale of targeting RGD-binding integrins to potentially inhibit viral cell infection and to block TGF-β activation, which is involved in the severity of several human pathologies, including the complications of severe COVID-19 cases. Furthermore, we demonstrate the correlation between ACE2 and TGF-β expression and the possible consequences for severe COVID-19 infections. Finally, we list approved drugs or drugs in clinical trials for other diseases that also target the RGD-binding integrins or TGF-β. These drugs have already shown a good safety profile and, therefore, can be faster brought into a trial to treat COVID-19 patients.
新型冠状病毒SARS-CoV-2是一场全球大流行疾病，也是一场严重的公共卫生危机。SARS-CoV-2具有高度传染性，且死亡率很高，尤其是在老年人和有基础疾病的患者中。在现阶段，尚无有效的药物可用于治疗这些患者。在本综述中，我们分析了靶向RGD结合整合素以潜在抑制病毒细胞感染并阻断TGF-β激活的基本原理，TGF-β激活与包括重症COVID-19病例并发症在内的多种人类疾病的严重程度有关。此外，我们证明了ACE2与TGF-β表达之间的相关性以及对重症COVID-19感染可能产生的后果。最后，我们列出了已获批的或正在进行针对其他疾病的临床试验的药物，这些药物也靶向RGD结合整合素或TGF-β。这些药物已经显示出良好的安全性，因此，可以更快地进入治疗COVID-19患者的试验。
